An experimental gene-editing therapy for hereditary angioedema (HAE), called NTLA-2002, has been administered to the first participant in the Phase 2 portion of a clinical trial, according to its developer, Intellia Therapeutics. “We are pleased to announce dosing has begun in the Phase 2 study of NTLA-2002,”…
A pregnant woman with type 3 hereditary angioedema (HAE) had potential swelling attacks effectively controlled during both pregnancy and breastfeeding with the use of subcutaneous or under-the-skin injections of a plasma-derived C1 esterase inhibitor (C1-INH), according to a case report from Spain. Researchers say this may be the first…
Preventive treatment with Orladeyo (berotralstat) for up to two years led to prolonged periods of no swelling attacks in people with hereditary angioedema (HAE), irrespective of age, gender, or prior preventive treatments, according to a post-hoc analysis of the Phase 2/3 APeX-S trial. “These data demonstrate how our…
A 48-year-old man developed angioedema after taking losartan, a medication commonly used to treat high blood pressure, a U.S. case study reported. Losartan, sold under the brand name Cozaar, is used to manage cardiovascular conditions, including lowering the risk of stroke with heart disease. To date, 20 reports have…
Insurance issues significantly affected the physical, psychological, and financial health of people with hereditary angioedema (HAE) in the U.S., according to a recent patient survey. Patients reported that health insurance delays and coverage denials led to more frequent HAE attacks, urgent care visits, missed work or school, and greater…
A woman with colon cancer developed angioedema as a side effect of treatment with an immune checkpoint inhibitor (ICI), a recently developed type of cancer immunotherapy. Researchers advised that “clinicians, pharmacists, and patients should be aware of this rare side effect of ICIs,” adding that facial angioedema can be…
People with hereditary angioedema due to C1-inhibitor deficiency (C1-INH-HAE) typically experience a significantly delayed diagnosis — even with a family history positive for the disease, according to a nationwide study in Latvia. Indeed, the median delay in obtaining a diagnosis in the Northern European country is 20.5 years, researchers…
Long-term treatment with Takhzyro (lanadelumab) was associated with quality of life gains among people with hereditary angioedema (HAE) who participated in the HELP open-label long-term extension (OLE) study. The study’s participants, who either rolled over from the Phase 3 HELP trial (NCT02586805), or were newly enrolled in…
Pharvaris’ PHVS416, a soft-gel capsule of PHA121, now also known as deucrictibant, continues to show promising safety and effectiveness for treating swelling attacks in people with hereditary angioedema (HAE). That’s according to data from RAPIDe-1 (NCT04618211), a Phase 2 clinical trial that’s comparing on-demand treatment with PHVS416…
The use of preventive therapy in hereditary angioedema (HAE) was found to reduce the number of HAE attacks requiring on-demand treatment, and also had an impact on productivity, with patients losing fewer work or school days, a study in Australia reported. However, prophylactic treatment did not seem to ease…
Get regular updates to your inbox.